Amylyx Pharmaceuticals (AMLX) Return on Sales (2023 - 2024)
Historic Return on Sales for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to 5.68%.
- Amylyx Pharmaceuticals' Return on Sales rose 1690900.0% to 5.68% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.68%, marking a year-over-year decrease of 44800.0%. This contributed to the annual value of 2.64% for FY2024, which is 27500.0% down from last year.
- As of Q3 2025, Amylyx Pharmaceuticals' Return on Sales stood at 5.68%, which was up 1690900.0% from 7.03% recorded in Q2 2025.
- Over the past 5 years, Amylyx Pharmaceuticals' Return on Sales peaked at 0.2% during Q2 2023, and registered a low of 538.34% during Q2 2022.
- Its 5-year average for Return on Sales is 101.31%, with a median of 7.03% in 2025.
- In the last 5 years, Amylyx Pharmaceuticals' Return on Sales soared by 5385400bps in 2023 and then tumbled by -1749600bps in 2024.
- Quarter analysis of 5 years shows Amylyx Pharmaceuticals' Return on Sales stood at 308.53% in 2021, then skyrocketed by 99bps to 1.65% in 2022, then surged by 102bps to 0.04% in 2023, then tumbled by -4081bps to 1.42% in 2024, then crashed by -301bps to 5.68% in 2025.
- Its Return on Sales was 5.68% in Q3 2025, compared to 7.03% in Q2 2025 and 7.9% in Q1 2025.